Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeted delivery into motor nerve terminals of inhibitors for SNARE-cleaving proteases via liposomes coupled to an atoxic botulinum neurotoxin.

The FEBS journal - 1 Jul 2012

Edupuganti Om P, Ovsepian Saak V, Wang Jiafu, Zurawski Tomas H, Schmidt James J, Smith Leonard, Lawrence Gary W, Dolly J Oliver

Abstract excerpt

A targeted drug carrier (TDC) is described for transferring functional proteins or peptides into motor nerve terminals, a pivotal locus for therapeutics to treat neuromuscular disorders. It exploits the pronounced selectivity of botulinum neurotoxin type B (BoNT/B) for interacting with acceptors on these cholinergic nerve endings and becoming internalized. The gene encoding an innocuous BoNT/B protease-inactive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Botulinum Toxins
Share to Diaphragm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fluorescein

Share to Paralysis

Share to Presynaptic Terminals

Share to SNARE Proteins

Share to Streptavidin

Share to Synaptosomal-Associated Protein 25

Source

Identifiers

PMID: 22607388
DOI: 10.1111/j.1742-4658.2012.08638.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeted delivery into motor nerve terminals of inhibitors for SNARE-cleaving proteases via liposomes coupled to an atoxic botulinum neurotoxin.PMID 22607388Read ↗

A dileucine in the protease of botulinum toxin A underlies its long-lived neuroparalysis: transfer of longevity to a novel potential therapeutic.Semantic proximity Read ↗

Novel therapeutics based on recombinant botulinum neurotoxins to normalize the release of transmitters and pain mediators.Semantic proximity Read ↗

Botulinum Toxin: A Comprehensive Review of Its Molecular Architecture and Mechanistic ActionSemantic proximity Read ↗

Botulinum Neurotoxins A and E Undergo Retrograde Axonal Transport in Primary Motor NeuronsSemantic proximity Read ↗

Challenges in searching for therapeutics against Botulinum NeurotoxinsSemantic proximity Read ↗

Botulinum toxin intoxication requires retrograde transport and membrane translocation at the ER in RenVM neuronsSemantic proximity Read ↗

Novel chimeras of botulinum and tetanus neurotoxins yield insights into their distinct sites of neuroparalysis.Semantic proximity Read ↗

Atoxic derivative of botulinum neurotoxin A as a prototype molecular vehicle for targeted delivery to the neuronal cytoplasm.Semantic proximity Read ↗

Characterization of a membrane binding loop leads to engineering botulinum neurotoxin B with improved therapeutic efficacy.Semantic proximity Read ↗

Light Chain Diversity among the Botulinum NeurotoxinsSemantic proximity Read ↗

Embracing the Versatility of Botulinum Neurotoxins in Conventional and New Therapeutic ApplicationsSemantic proximity Read ↗

Therapeutic Applications of Botulinum Neurotoxins in Veterinary MedicineSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.